FRANCESCO PETRELLA*, ENRICO MARIO CASSINA, LIDIA LIBRETTI, EMANUELE PIRONDINI, FEDERICO RAVEGLIA, ANTONIO TUORO
Oncology Research, Vol.32, No.3, pp. 433-437, 2024, DOI:10.32604/or.2023.046497
- 06 February 2024
Abstract The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues, thus incrementing drug effects and, at the same time, reducing the damage of non-involved tissues to cytotoxic agents. Mesenchymal stromal cells (MSC) represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells. During the last year, they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cells, thus optimizing cytotoxic action on cancer cells, while More >
Login
Register
